---
title: "ESMO 2025：基石药业-B 揭晓 CS2009(PD-1/VEGF/CTLA-4 三特异性抗体)Ⅰ期临床试验数据"
description: "智通财经 APP 讯，基石药业-B 发布公告，公司在 2025 年欧洲肿瘤内科学会 (ESMO) 年会上首次发表 CS2009(PD1/VEGF/CTLA-4 三特异性抗体) 的 I 期临床研究初步数据和 CS5001(ROR1 抗体偶联药物 ADC) 的 Ib 期临床研究设计。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261789427.md"
published_at: "2025-10-20T01:03:08.000Z"
---

# ESMO 2025：基石药业-B 揭晓 CS2009(PD-1/VEGF/CTLA-4 三特异性抗体)Ⅰ期临床试验数据

> 智通财经 APP 讯，基石药业-B 发布公告，公司在 2025 年欧洲肿瘤内科学会 (ESMO) 年会上首次发表 CS2009(PD1/VEGF/CTLA-4 三特异性抗体) 的 I 期临床研究初步数据和 CS5001(ROR1 抗体偶联药物 ADC) 的 Ib 期临床研究设计。

智通财经 APP 讯，基石药业-B(02616) 发布公告，公司在 2025 年欧洲肿瘤内科学会 (ESMO) 年会上首次发表 CS2009(PD1/VEGF/CTLA-4 三特异性抗体) 的 I 期临床研究初步数据和 CS5001(ROR1 抗体偶联药物 ADC) 的 Ib 期临床研究设计。

### Related Stocks

- [02616.HK - 基石药业-B](https://longbridge.com/zh-CN/quote/02616.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone secures FDA clearance to begin CS2009 Phase II trial | CStone Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase II trial f | [Link](https://longbridge.com/zh-CN/news/276114397.md) |
| CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II clinical trial of its t | [Link](https://longbridge.com/zh-CN/news/276018493.md) |
| 13:03 ETBelay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) | Belay Diagnostics has announced the validation of its Summit™ 2.0 Comprehensive Genomic Profile assay for cerebrospinal  | [Link](https://longbridge.com/zh-CN/news/276259162.md) |
| CStone Pharmaceuticals Unveils Phase I Data for CS2009 Trispecific Antibody at ESMO 2025 | CStone Pharmaceuticals has revealed preliminary Phase I clinical data for its trispecific antibody CS2009, targeting PD- | [Link](https://longbridge.com/zh-CN/news/261784961.md) |
| CStone Pharmaceuticals to Present Phase I Dose Escalation Data for Trispecific Antibody and Update on ROR1 ADC at ESMO 2025 | CStone Pharmaceuticals will present new clinical data at the ESMO Congress 2025 in Berlin, from October 17 to 21. The co | [Link](https://longbridge.com/zh-CN/news/260804437.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。